Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934342 | 0.89 | OPRD1 (0.51) | OPRD1MTNR1BACEOPRM1OPRK1 | |
| SCHEMBL14959494 | 0.87 | ACE (0.41) | OPRD1MTNR1BMTNR1AACEOPRM1 | |
| SCHEMBL11929933 | 0.86 | OPRD1 (0.47) | OPRD1MTNR1BACEDRD1MEN1 | |
| SCHEMBL14959567 | 0.85 | MTNR1B (0.52) | OPRD1MTNR1BMTNR1ACYP2D6CYP3A4 | |
| SCHEMBL8227352 | 0.83 | CYP3A4 (0.57) | MTNR1BMTNR1ACYP2D6CYP3A4CYP2C19 | |
| SCHEMBL8230760 | 0.78 | MAPK1 (0.57) | OPRD1MTNR1BMTNR1ACYP2D6CYP3A4 | |
| SCHEMBL9815267 | 0.76 | OPRD1 (0.61) | OPRD1MTNR1BACEOPRK1DRD1 | |
| SCHEMBL7152377 | 0.76 | ACE (0.60) | MTNR1BMTNR1ACYP2D6ACEHHAT | |
| Hydrochloric Acid SCHEMBL9815293 | 0.76 | OPRD1 (0.60) | OPRD1MTNR1BACEOPRK1DRD1 | |
| SCHEMBL12187751 | 0.75 | MTNR1B (0.49) | OPRD1MTNR1BOPRM1OPRK1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | OPRD1 147/4885MTNR1B 346/4885MTNR1A 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.